-+ 0.00%
-+ 0.00%
-+ 0.00%

Tonix Pharmaceuticals Expects Cash Runway Into Early Q3 2027

PUBT·11/09/2026 14:31:34
Listen to the news
Tonix Pharmaceuticals Expects Cash Runway Into Early Q3 2027
  • Tonix Pharmaceuticals expects its cash runway to extend into early third-quarter 2027.
  • Cash and cash equivalents totaled about $163 million as of September 30, 2026, with no debt.
  • Third-quarter net revenue reached $17.2 million, including $15 million from TONMYA.
  • TONMYA net sales rose 37% from the prior quarter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.